Phaseline

Targets › INTEGRASE

INTEGRASE: drug programs, companies and trials

8 programs from 6 companies in 52 trials: 15 Phase 3, 14 Phase 4, 12 Phase 2, 11 Phase 1; Infectious disease, Other, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: the race on INTEGRASE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Instituto Mexicano del Seguro SocialDTG/3TC
Dolutegravir (integrase strand transfer inhibitor) and lamivudine (nucleoside reverse tran
INTEGRASE, TCEA1Phase 4HIV InfectionDec 2026
Harvard School of Public Health (HSPH)DTG/ABC/3TC
Integrase strand transfer inhibitor (dolutegravir) combined with nucleoside reverse transc
INTEGRASE, ABCC4, POLR2APhase 4HIVDec 2026
José Antonio Mata MarínDTG/3TC
Integrase strand transfer inhibitor (INSTI) + nucleoside reverse transcriptase inhibitor (
INTEGRASE, POLR2APhase 4HIV Infections–
GSKCabotegravir
Human immunodeficiency virus type 1 integrase inhibitor
INSTI, INTEGRASEPhase 3HIV Infections; Infection, Human Immunodeficiency Virus; Pre-exposure Prophylaxis; HIV-1 Infected Adults With Controlled Viremia …Mar 2027
GSKDolutegravir
Human immunodeficiency virus type 1 integrase inhibitor
INSTI, RTASE, INTEGRASE, RTPhase 3HIV; HIV Infections; HIV-1-infection; Acute HIV Infection …Mar 2027
Gilead SciencesBictegravir
Human immunodeficiency virus type 1 integrase inhibitor
INTEGRASE, ABCC10Phase 3HIV-1-infection; HIV-1 Infection; HIV -1 Infection; HIV InfectionsJun 2027
Gilead SciencesLepetegravir
Integrase strand transfer inhibitor (INSTI)
INTEGRASEPhase 2HIV-1-InfectionJan 2028
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaRaltegravir
Human immunodeficiency virus type 1 integrase inhibitor
INTEGRASEPhase 2HIV Infections–

Conditions

HIV Infections (22) HIV-1-infection (11) HIV (5) HIV -1 Infection (2) Infection, Human Immunodeficiency Virus (1) Pre-exposure Prophylaxis (1) HIV-1 Infected Adults With Controlled Viremia (1) Pre-Exposure Prophylaxis (PrEP) (1) Hiv (1) HIV Infection (1) Acute HIV Infection (1) Healthy Volunteer (1)

Modalities

small molecule (7), mixed (1)

Companies

GSK (2) Gilead Sciences (2) José Antonio Mata Marín (1) Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida (1) Instituto Mexicano del Seguro Social (1) Harvard School of Public Health (HSPH) (1)

Related targets

INSTI (2) POLR2A (2) TCEA1 (1) RTASE (1) RT (1) ABCC10 (1) ABCC4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.